Receptor Integral To Or Derived From A Lymphocytic Or Lymphocytic-like Cell (e.g., Nk Cell, Etc.) Patents (Class 424/144.1)
-
Patent number: 9758589Abstract: Methods are provided to enhance the efficacy of antibody therapy directed to tumor cells.Type: GrantFiled: November 14, 2014Date of Patent: September 12, 2017Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Holbrook Kohrt, Roch Houot, Ronald Levy, Arash Ash Alizadeh, Matthew J. Goldstein, James Torchia
-
Patent number: 9732149Abstract: Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis. Chronic eculizumab treatment appears to be a safe and effective therapy for PNH.Type: GrantFiled: October 3, 2016Date of Patent: August 15, 2017Assignee: Alexion Pharmaceuticals, Inc.Inventors: Leonard Bell, Russell P. Rother, Mark J. Evans
-
Patent number: 9731001Abstract: The invention is concerned with compounds, pharmaceutical compositions, screening methods, and therapeutic methods for preventing or reducing a human immunodeficiency virus type-1 (HIV-1) infection and/or propagation associated with dendritic cell immunoreceptor (DCIR). Described herein are compounds which bind on at least one three-dimensional cavity of the DCIR, the cavity(ies) being involved in the interaction between HIV-1 and DCIR. Also described are screening methods for identifying active inhibitors and method of using such inhibitors for the prevention or treatment of virus infections, and more particularly for reducing human immunodeficiency virus type-1 (HIV-1) binding, entry and/or replication in human cells.Type: GrantFiled: December 20, 2012Date of Patent: August 15, 2017Assignee: Universite LavalInventors: Caroline Gilbert, Michel J. Tremblay, Sheng-Xiang Lin, Arezki Azzi, Alexandra Lambert
-
Patent number: 9713636Abstract: A highly stable nucleic acid-polysaccharide complex of an siRNA and schizophyllan is formed by adding polydeoxyadenine in which at least part of the phosphodiester link portion is phosphorothioated to an siRNA and allowing the siRNA and schizophyllan to form a complex.Type: GrantFiled: February 15, 2012Date of Patent: July 25, 2017Assignee: NAPAJEN PHARMA, INC.Inventors: Ko Rii, Kazuo Sakurai, Masakazu Kobayashi, Hironori Ando, Sadaharu Higuchi, Shiro Takahara
-
Patent number: 9657068Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.Type: GrantFiled: February 15, 2011Date of Patent: May 23, 2017Assignee: Ultimovacs ASInventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
-
Patent number: 9657094Abstract: Methods, processes, systems, and compositions for treating disease are disclosed. In some cases, the present disclosure provides for delivery of therapeutic agents, in an active form, to a localized area, over an extended period of time. In one embodiment, the disclosed composition may comprise a therapeutic agent and a biodegradable polymer and/or a biodegradable polymer microsphere.Type: GrantFiled: June 24, 2014Date of Patent: May 23, 2017Assignee: Colorado School of MinesInventor: Melissa D. Krebs
-
Patent number: 9642910Abstract: The object of the present invention is to provide a new therapeutic method and a new therapeutic agent that are different from known therapeutic medicines for human T cell leukemia virus type-1 (also known as human T lymphotropic virus type-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers. The present invention relates to a therapeutic method and a therapeutic agent for human T cell leukemia virus type-1 (HTLV-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers (ACs), which is characterized by reducing HTLV-1 virus-infected cells using an anti-human CC-chemokine receptor 4 (CCR4) antibody.Type: GrantFiled: July 8, 2013Date of Patent: May 9, 2017Assignees: St. Marianna University School of Medicine, KYOWA HAKKO KIRIN CO., LTDInventor: Yoshihisa Yamano
-
Patent number: 9593147Abstract: This invention relates to: a peptide which comprises an amino acid sequence consisting of 12 to 18 amino acid residues represented by (X1-3)āCā(X8-10)āCā(X1-3) wherein each X independently represents an arbitrary amino acid residue other than cysteine, and C represents a cysteine residue, and is capable of binding to human IgA; and to a method for analyzing or purifying human IgA using the peptide.Type: GrantFiled: May 24, 2011Date of Patent: March 14, 2017Assignees: Kagoshima University, Otsuka Chemical Co., Ltd.Inventor: Yuji Ito
-
Patent number: 9567367Abstract: Disclosed are peptides and methods for the treatment of bacterial infections and associated inflammation. Effective doses and treatment protocols are disclosed.Type: GrantFiled: January 16, 2013Date of Patent: February 14, 2017Assignee: ATOX BIO LTD.Inventors: Anat Shirvan, Dan Teleman, Gila Arad, Raymond Kaempfer
-
Patent number: 9562098Abstract: The invention relates to humanized antibodies directed against the human lymphocyte receptor CD28. When used in a monovalent form these antibodies are antagonists, i.e. capable of blocking of the CD28/B7 interaction, without activating CD28. These antibodies can be used in particular as therapeutic agents for blocking T cell activation through the CD28 receptor.Type: GrantFiled: July 8, 2014Date of Patent: February 7, 2017Assignees: OSE Immunotherapeutics, Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Caroline Mary, Nicolas Poirier, Bernard Vanhove
-
Patent number: 9556279Abstract: Among N-glycoside-linked sugar chains which are bound to the Fc region of an antibody, sugar chains which are bound to Asn at position 297 relates to the activity and stability of the antibody in blood, but there is a possibility that extra sugar chains bound to the amino acid residues at positions other than 297 have influences upon the antibody constant region-mediated activity and a possibility of causing a problem of uniformity as a therapeutic antibody preparation. Accordingly, among N-glycoside-linked sugar chains which bind to the Fc region of the antibody, a method for controlling extra sugar chains which are bound to Asn residues at positions other than position 297 according to the EU index is required.Type: GrantFiled: March 2, 2011Date of Patent: January 31, 2017Assignee: KYOWA HAKKO KIRIN CO., LTD.Inventors: Rinpei Niwa, Mami Tsuchiya
-
Patent number: 9540433Abstract: Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.Type: GrantFiled: February 1, 2012Date of Patent: January 10, 2017Assignee: GENMAB A/SInventors: Sandra Verploegen, Marije Overdijk, Riemke Van Dijkhuizen, Willem Karel Bleeker, Patrick Van Berkel, Paul Parren, Steen Lisby
-
Patent number: 9526702Abstract: The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comprising at last one targeting moiety and optionally at least one immunostimulatory agent. The invention provides pharmaceutical compositions comprising inventive vaccine nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive vaccine nanocarriers and pharmaceutical compositions thereof. The invention provides methods of prophylaxis and/or treatment of diseases, disorders, and conditions comprising administering at least one inventive vaccine nanocarrier to a subject in need thereof.Type: GrantFiled: March 15, 2013Date of Patent: December 27, 2016Assignees: Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc., President and Fellows of Harvard College, The Children's Medical Center CorporationInventors: Ulrich H. von Andrian, Omid C. Farokhzad, Robert S. Langer, Tobias Junt, Elliott Ashley Moseman, Liangfang Zhang, Pamela Basto, Matteo Iannacone, Frank Alexis
-
Patent number: 9434785Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.Type: GrantFiled: November 9, 2015Date of Patent: September 6, 2016Assignee: Kymab LimitedInventors: Philip Bland-Ward, Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosmac, Leslie Susan Kean, Victor Tkachev
-
Patent number: 9427463Abstract: The invention provides methods for treating a malignant neoplastic cell proliferative disorder or disease, comprising administering to a subject in need thereof an effective amount of an mTOR inhibitor and an effective amount of a CD4 lymphocyte depleting agent. Such methods find utility in the treatment of certain subsets of malignant neoplastic cell proliferative disorders or diseases, e.g. renal cell carcinoma and melanoma. The invention also provides for pharmaceutical compositions comprising a therapeutically effective amount of an mTOR inhibitor and an effective amount of a CD4 lymphocyte depleting agent in a pharmaceutically acceptable carrier.Type: GrantFiled: November 10, 2014Date of Patent: August 30, 2016Assignee: Cedars-Sinai Medical CenterInventors: Hyung Kim, Yanping Wang
-
Patent number: 9418203Abstract: A system for annotating genomic variant files includes an application server, an annotation database, a genomic database, and an annotation processing computer system. The genomic database may be graph-oriented. The annotation processing computer system processes can process variant files in batch modes and includes annotation modules designed to improve the speed of the annotation process. The batch modes may include batch transmission, and/or batch annotation.Type: GrantFiled: March 15, 2013Date of Patent: August 16, 2016Assignee: Cypher Genomics, Inc.Inventors: Phillip Pham, Salil Deshpande
-
Patent number: 9358306Abstract: The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.Type: GrantFiled: June 27, 2012Date of Patent: June 7, 2016Assignee: The United States of America, as rep. by the Secretary, Dept. of Health and Human ServicesInventors: Hisataka Kobayashi, Peter Choyke, Marcelino Bernardo
-
Patent number: 9345739Abstract: The present invention is directed to methods of treating proteinuric diseases by the administration of av?3 integrin inhibitors.Type: GrantFiled: November 7, 2008Date of Patent: May 24, 2016Assignee: The General Hospital CorporationInventor: Jochen Reiser
-
Patent number: 9333219Abstract: Methods and compositions are provided for inhibiting or treating a herpesvirus infection in a subject using inhibitors of mammalian Akt.Type: GrantFiled: July 25, 2013Date of Patent: May 10, 2016Assignee: Albert Einstein College of Medicine, Inc.Inventors: Betsy Herold, Natalia Cheshenko
-
Patent number: 9321831Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.Type: GrantFiled: September 13, 2013Date of Patent: April 26, 2016Assignee: MedImmune LimitedInventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
-
Patent number: 9296823Abstract: Antibodies that bind to a GPR49 protein and have cell proliferation inhibitory activity against cells expressing the GPR49 protein are disclosed. Cell proliferation inhibitory activities are cytotoxic activities such as antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. Pharmaceutical compositions, cell-proliferation inhibitors, and anticancer agents containing an antibody of the present invention as an active ingredient are also disclosed. Examples of cancer include gastric cancer, colon cancer, hepatocellular carcinoma, lung cancer, prostate cancer, ovarian cancer, Ewing's sarcoma, and glioma. Furthermore, methods for diagnosing cancer by detecting expression of a GPR49 protein or a gene encoding a GPR49 protein, and diagnostic agents and kits to be used in these methods are also disclosed.Type: GrantFiled: February 5, 2014Date of Patent: March 29, 2016Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHAInventor: Shinichi Funahashi
-
Patent number: 9243052Abstract: The invention relates to methods for treating and diagnosing hematologic malignancies, Chronic lymphocytic leukemia and Small Lymphocytic Lymphoma in particular, using PD-1 ligands (PD-L1, PD-L2, or anti-PD-1 antibodies).Type: GrantFiled: August 14, 2008Date of Patent: January 26, 2016Inventors: Daniel Olive, Luc Xerri, Alemseged Truhneh
-
Patent number: 9217037Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.Type: GrantFiled: September 3, 2013Date of Patent: December 22, 2015Assignees: BIOCON LIMITED, CENTRO DE INMUNOLGIA MOLECULARInventors: Ramakrishnan Melarkode, Pradip Nair, Sundaraj David Rajkumar, Kedarnath Nanjund Sastry, Monalisa Chatterji, Laxmi Adhikary, Hema Balasubramanian, Jose Enrique Montero Casimiro, Josefa Lombardero Valladares, Rolando Perez Rodriguez
-
Patent number: 9205148Abstract: The present invention relates to antibodies and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to B7-H1 or PD-1. In some embodiments such molecules are additionally capable of modulating the ability of B7-H1 or B7-DC to bind to PD-1 or are capable of affecting the signaling activity of the B7-H1 or PD-1. The invention additionally concerns the uses of such molecules in the diagnosis and treatment of cancer and other diseases.Type: GrantFiled: April 19, 2012Date of Patent: December 8, 2015Assignee: MedImmune, LLCInventors: Solomon Langermann, Linda Liu, Shannon Marshall, Sheng Yao
-
Patent number: 9206253Abstract: An isolated antibody that specifically binds to at least one of canine Interleukin-31 (IL-31) or feline IL-31 is provided. Such antibodies can be in the form of diagnostic and/or veterinary compositions useful for treating a pruritic and/or allergic condition in dogs or cats.Type: GrantFiled: July 8, 2014Date of Patent: December 8, 2015Assignee: Zoetis Services LLCInventors: Gary F. Bammert, Steven A Dunham
-
Patent number: 9194778Abstract: Provided are compositions, kits, and methods for separating cells including complexes of at least one type of linker capable of binding to an antibody or antigen binding fragment and a solid phase.Type: GrantFiled: April 23, 2013Date of Patent: November 24, 2015Assignee: SAMSUNG ELECTRONICS CO., LTD.Inventors: Kyung-yeon Han, Yeon-jeong Kim, Jong-myeon Park, Chang-eun Yoo
-
Patent number: 9169322Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.Type: GrantFiled: January 19, 2012Date of Patent: October 27, 2015Assignee: Vaccibody ASInventors: Bjarne Bogen, Agnete Brunsvik Fredriksen, Inger Sandlie
-
Patent number: 9134310Abstract: A mammalian C-type lectin receptor type is identified which is shown to bind IgG antibodies or Fc fragments, thus inducing IVIG-related reversal of inflammation associated with various immune disorders. The identification of a DC-SIGN receptor type which interacts with IgG to promote a biological response reducing inflammation associated with immune disorders provides for methods of screening and selecting compounds which may be useful in treating various immune disorders by acting to modulate a DC-SIGN(+) cell to signal a second effector macrophage, causing an increase in expression of the Fc?RIIB receptor and in turn inhibiting a cellular-mediated inflammatory response.Type: GrantFiled: November 19, 2010Date of Patent: September 15, 2015Assignee: The Rockefeller UniversityInventors: Jeffrey V. Ravetch, Robert M Anthony
-
Patent number: 9109037Abstract: The present invention features anti-SOD1 antibodies and methods of using the antibodies for the treatment of amyotrophic lateral sclerosis (ALS) or the amelioration of symptoms associated with ALS.Type: GrantFiled: October 25, 2011Date of Patent: August 18, 2015Assignee: University of MassachusettsInventors: Donna Ambrosino, Gregory Babcock, Teresa Broering, Zuoshang Xu
-
Patent number: 9102734Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.Type: GrantFiled: March 4, 2010Date of Patent: August 11, 2015Assignee: Baylor Research InstituteInventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Peter Klucar, Keiko Akagawa, Sandra Zurawski, SangKon Oh
-
Patent number: 9089572Abstract: One aspect of the invention relates to compounds that inhibit the activity of p97, such as by binding covalently to a cysteine residue in the active site. In certain embodiments, the invention relates to the treatment of disease, such as cancer, comprising administering a compound of the invention.Type: GrantFiled: January 20, 2009Date of Patent: July 28, 2015Assignees: California Institute of Technology, The Scripps Research InstituteInventors: Steven J. Brown, Tsui-Fen Chou, Raymond Deshaies, Amanda C. Jones, Hugh Rosen, Brian M. Stoltz
-
Patent number: 9072798Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.Type: GrantFiled: February 17, 2010Date of Patent: July 7, 2015Assignee: Ludwig Institute for Cancer Research LTD.Inventors: Gerd Ritter, Anne Murray, George Mark, Christoph Renner
-
Patent number: 9040041Abstract: The present invention relates to Fc variants with optimized Fc receptor binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc receptor binding properties, and methods for using Fc variants with optimized Fc receptor binding properties.Type: GrantFiled: June 4, 2010Date of Patent: May 26, 2015Assignee: Xencor, Inc.Inventors: John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, John O. Richards, Gregory L. Moore, David F. Carmichael
-
Patent number: 9035026Abstract: The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. Fc?RIIIA), and in particular binding molecules that specifically bind the A form Fc?RIII but do not bind to the B form of Fc?RIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.Type: GrantFiled: May 26, 2006Date of Patent: May 19, 2015Assignee: Affimed GMBHInventors: Karin Hoffmann, Sergey Kipriyanov, Stefan Knackmuss, Fabrice Le Gall, Melvyn Little, Uwe Reusch
-
Publication number: 20150132316Abstract: The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders.Type: ApplicationFiled: January 12, 2015Publication date: May 14, 2015Inventors: ALESSANDRO MORETTA, EMANUELA MARCENARO, FRANCOIS ROMAGNE, PASCALE ANDRE
-
Patent number: 9028826Abstract: Improved anti-CD154 antibodies are provided herein which have ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein.Type: GrantFiled: March 13, 2013Date of Patent: May 12, 2015Assignee: The Trustees of Dartmouth CollegeInventor: Randolph J. Noelle
-
Patent number: 9028824Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.Type: GrantFiled: May 17, 2012Date of Patent: May 12, 2015Assignees: Pfizer Inc., Bristol-Myers Squibb CompanyInventors: Jing Min, Yanli Wu, Rory F. Finn, Barrett R. Thiele, Wei Liao, Ronald P. Gladue, Arvind Rajpal, Timothy J. Paradis, Peter Brams, Brigitte Devaux, Yi Wu, Kristopher Toy, Heidi N. LeBlanc, Haichun Huang
-
Patent number: 9028815Abstract: The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds Fc?RIIIA and/or Fc?RIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by Fc?R is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.Type: GrantFiled: July 13, 2011Date of Patent: May 12, 2015Assignee: MacroGenics, Inc.Inventors: Jeffrey Stavenhagen, Sujata Vijh, Christopher Rankin, Sergey Gorlatov, Ling Huang
-
Publication number: 20150125466Abstract: The present invention relates to method for predicting a subject's relative response to cancer immunotherapy treatment. The methods involve providing a sample comprising a tumor cell or a peripheral blood cell from the subject; measuring the expression level of matrix metalloproteinase-23 (āMMP-23ā) by the tumor cell or the peripheral blood cell; comprising the measured expression level of MMP-23 with a control or standard value; and determining the subject's predicted response to cancer immunotherapy, where, based on said comparing, a higher MMP-23 expression level compared to the control or standard value predicts the subject will have a poor response to cancer immunotherapy. The present invention also relates to methods for increasing production of tumor infiltrating leucocytes (āTILsā) in a subject, methods of identifying a subject as a candidate for adoptive T-cell therapy using T-cells that primarily express KCa3.Type: ApplicationFiled: May 1, 2013Publication date: May 7, 2015Inventors: Michelle Krogsgaard, Iman Osman
-
Patent number: 9017679Abstract: Compositions and methods utilizing immunomodulating agents can either stimulate or indirectly augment the immune system or have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used to treat disease caused by asthma and chronic inflammation such as inflammatory bowel diseases including ulcerative colitis and Crohn's Disease. TNFR25 antagonists disclosed herein are capable of inhibiting CD8 T cell-mediated cellular immune responses and can for example, mitigate organ or tissue rejection following a tissue transplantation.Type: GrantFiled: April 27, 2012Date of Patent: April 28, 2015Assignee: University of MiamiInventors: Eckhard R. Podack, Vadim Deyev, Robert Levy
-
Patent number: 9017682Abstract: Methods, uses, agents and compositions useful for the diagnosis, prevention and/or treatment of inflammatory conditions, such as neuroinflammatory conditions such as multiple sclerosis, and for the identification and selection of inflammatory cytokine-secreting T cell or a precursor thereof, based on the expression and/or modulation of melanoma cell adhesion molecule (MCAM) are disclosed.Type: GrantFiled: September 14, 2012Date of Patent: April 28, 2015Assignee: Val-Chum, Limited PartnershipInventors: Alexandre Prat, Romain Cayrol, Nathalie Arbour
-
Publication number: 20150110779Abstract: The invention described herein relates to diagnostic and therapeutic methods and compositions useful for predicting the likelihood a cancer patient will experience a gastrointestinal immune-related adverse event (GI-irAE) after administration of a pharmaceutically acceptable amount of an activator of the immune system.Type: ApplicationFiled: March 15, 2013Publication date: April 23, 2015Inventors: Vafa Shahabi, Ruiru Ji
-
Patent number: 9005619Abstract: Methods of enhancing the efficacy of antibody-directed cellular cytotoxicity (ADCC) for therapy directed to killing of tumor cells are disclosed. Cancer specific cell surface antigens are bound by monoclonal antibodies, thereby stimulating a cytotoxic T cell response characterized by an upregulation of cell surface expression of costimulatory molecules on the T cell. The ADCC response is augmented by the subsequent administration of a second antibody that is an agonist of the costimulatory molecule.Type: GrantFiled: December 7, 2010Date of Patent: April 14, 2015Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Holbrook Kohrt, Roch Houot, Ronald Levy, Arash Ash Alizadeh, Matthew J. Goldstein, James Torchia
-
Patent number: 8999339Abstract: The present invention provides methods of treating a mammal having chronic obstructive pulmonary disease (COPD), independent of both smoking status and asthma status, with a therapeutically effective amount of an anti-IgE moiety. In accordance with the invention, COPD patients with an elevated serum IgE level may benefit from the treatment methods disclosed. In certain instances, the methods of the disclosure have been found to be useful for the treatment of COPD patients regardless of their skin test results and/or in vitro reactivity to a perennial aeroallergen. Anti-IgE moieties, in accordance with the invention, include but are not limited to any IgG antibody that selectively binds to a given mammal immunoglobulin E (e.g., human immunoglobulin E) such as humanized anti-IgE, humanized murine monoclonal antibody, and/or Omalizumab.Type: GrantFiled: June 6, 2014Date of Patent: April 7, 2015Inventor: Clifford G. Risk
-
Publication number: 20150093355Abstract: The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient; and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib; or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036; or is selected from the group consisting of dasatinib and nilotinib.Type: ApplicationFiled: October 17, 2014Publication date: April 2, 2015Applicant: CSL LIMITEDInventors: Devendra Keshaorao HIWASE, Timothy Peter HUGHES, Angel Francisco LOPEZ, Gino Luigi VAIRO
-
Patent number: 8993731Abstract: A humanized agonistic antibody which binds human PD-1 comprising a heavy chain wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO: 2 for CDR-H2 and the sequence given in SEQ ID NO: 3 for CDR-H3 and the heavy chain framework region is derived from human sub-group sequence VH4 3-1 4-30.4+JH4 (SEQ ID NO: 33). The disclosure also extends to therapeutic uses of the antibody molecules, compositions and methods for producing said antibody molecules.Type: GrantFiled: March 9, 2011Date of Patent: March 31, 2015Assignee: UCB Biopharma SPRLInventor: Kerry Louise Tyson
-
Publication number: 20150064197Abstract: The invention provides novel methods of administering anti-CD3 antibodies, e.g., via oral or mucosal delivery. The invention also provides methods of treating, preventing, or delaying the onset of autoimmune disorders by oral or mucosal administration of anti-CD3 antibodies. Finally, the invention provides compositions including anti-CD3 antibodies, suitable for oral or mucosal administration.Type: ApplicationFiled: November 7, 2014Publication date: March 5, 2015Inventors: Howard Weiner, Mohamed H. Sayegh
-
Publication number: 20150064196Abstract: The present disclosure provides hetero-bicyclic compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, hydrates, N-oxides, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by Bruton's tyrosine kinase (Btk) activity, The disclosure also relates to the process of preparation of compounds of Formula (I). These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of Bruton's tyrosine kinase (Btk), such as inflammatory and/or autoimmune disorder, cell proliferation, rheumatoid arthritis, psoriasis, psoriatic arthritis, transplant rejection, graft-versus-host disease, multiple sclerosis, inflammatory bowel disease, allergic diseases, asthma, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, B-cell malignancies, systemic lupus, erythematosus or other disorders.Type: ApplicationFiled: October 8, 2014Publication date: March 5, 2015Inventors: Mahesh Thakkar, Summon Koul, Debnath Bhuniya, Kasim Mookhtiar, Santosh Kurhade, Yogesh Munot, Tanaji Mengawade, Bheemashankar A. Kulkarni
-
Patent number: 8968730Abstract: The present invention relates to antibodies or fragments thereof that specifically bind the extracellular domain of Fc?RIIB, particularly human Fc?RIIB, and block the Fc binding site of human Fc?RIIB. The invention provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.Type: GrantFiled: July 3, 2008Date of Patent: March 3, 2015Assignee: MacroGenics Inc.Inventors: Scott Koenig, Maria Concetta Veri, Nadine Tuaillon
-
Patent number: 8968739Abstract: The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-?? TCR antibodies and antibody fragments. Anti-?? TCR antibodies are antibodies which bind to a ?? TCR. Anti-?? TCR antibodies produced by the hybridoma TOL101 MCB are also provided.Type: GrantFiled: July 19, 2013Date of Patent: March 3, 2015Assignee: Tolera Therapeutics, Inc.Inventors: Daniel R. Getts, James J. Herrmann, John J. Puisis, Frank J. Fokta